Translational Research in Malignancy
The Translational Research in Malignancy (TRIM) program is a highly interactive translational cancer research program. Its main objective is to conduct studies centered on molecular mechanisms of cancer progression and therapeutic resistance and to translate basic science and preclinical discoveries into early diagnosis, biomarkers, and cancer therapeutics. TRIM also connects the basic and population science programs to the clinic and facilitates the conversion of basic science discoveries to clinical trials.
Scientific Aims
- Characterize and target molecular mechanisms of cancer initiation and progression.
- Understand and overcome mechanisms of resistance to cancer treatment.
- Translate scientific discoveries into novel therapeutic clinical trials.
Program Leaders
- Daniela Matei, MD, is a leading physician-scientist who has contributed significantly to improving the treatment of ovarian cancer.
- Roger Stupp, MD, focuses on innovative cancer treatments and drug development, notably for brain tumors and brain metastases.
- Lucy Godley, MD, PhD, is an expert in cancer genetics with special emphasis in hematological malignancies.
Research Initiatives & Grants
- Prostate Cancer SPORE
A NCI award funds our SPORE (Specialized Program of Research Excellence) in prostate cancer. - Brain Tumor SPORE
A NCI award funds our SPORE (Specialized Program of Research Excellence) in brain tumors. - Translational Bridge Program
Established to foster innovative, high-impact research and to support translation of this research into clinical advancements - OncoSET Precision Medicine
OncoSET’s innovative three-step process uses next-generation genomic sequencing to target tumors from any type of cancer that is not responsive to standard forms of treatment.
Members
TRIM members work to understand mechanisms of resistance to cancer therapy, develop biomarkers linked to treatment response, and to test and develop novel therapies in preclinical models and innovative clinical trials. The overall goal of the program is to develop robust diagnostic and treatment strategies across a wide spectrum of solid tumors and hematological malignancies in adult and pediatric populations.